These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1036 related articles for article (PubMed ID: 25849828)

  • 21. HIV/AIDS Vaccine Candidates Based on Replication-Competent Recombinant Poxvirus NYVAC-C-KC Expressing Trimeric gp140 and Gag-Derived Virus-Like Particles or Lacking the Viral Molecule B19 That Inhibits Type I Interferon Activate Relevant HIV-1-Specific B and T Cell Immune Functions in Nonhuman Primates.
    García-Arriaza J; Perdiguero B; Heeney JL; Seaman MS; Montefiori DC; Yates NL; Tomaras GD; Ferrari G; Foulds KE; Roederer M; Self SG; Borate B; Gottardo R; Phogat S; Tartaglia J; Barnett SW; Burke B; Cristillo AD; Weiss DE; Lee C; Kibler KV; Jacobs BL; Wagner R; Ding S; Pantaleo G; Esteban M
    J Virol; 2017 May; 91(9):. PubMed ID: 28179536
    [TBL] [Abstract][Full Text] [Related]  

  • 22. An SHIV DNA/MVA rectal vaccination in macaques provides systemic and mucosal virus-specific responses and protection against AIDS.
    Wang SW; Bertley FM; Kozlowski PA; Herrmann L; Manson K; Mazzara G; Piatak M; Johnson RP; Carville A; Mansfield K; Aldovini A
    AIDS Res Hum Retroviruses; 2004 Aug; 20(8):846-59. PubMed ID: 15320989
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Critical role for Env as well as Gag-Pol in control of a simian-human immunodeficiency virus 89.6P challenge by a DNA prime/recombinant modified vaccinia virus Ankara vaccine.
    Amara RR; Smith JM; Staprans SI; Montefiori DC; Villinger F; Altman JD; O'Neil SP; Kozyr NL; Xu Y; Wyatt LS; Earl PL; Herndon JG; McNicholl JM; McClure HM; Moss B; Robinson HL
    J Virol; 2002 Jun; 76(12):6138-46. PubMed ID: 12021347
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Gp120-alum boosting of a Gag-Pol-Env DNA/MVA AIDS vaccine: poorer control of a pathogenic viral challenge.
    Buge SL; Ma HL; Amara RR; Wyatt LS; Earl PL; Villinger F; Montefiori DC; Staprans SI; Xu Y; Carter E; O'Neil SP; Herndon JG; Hill E; Moss B; Robinson HL; McNicholl JM
    AIDS Res Hum Retroviruses; 2003 Oct; 19(10):891-900. PubMed ID: 14585221
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Evaluation in rhesus macaques of Tat and rev-targeted immunization as a preventive vaccine against mucosal challenge with SHIV-BX08.
    Verrier B; Le Grand R; Ataman-Onal Y; Terrat C; Guillon C; Durand PY; Hurtrel B; Aubertin AM; Sutter G; Erfle V; Girard M
    DNA Cell Biol; 2002 Sep; 21(9):653-8. PubMed ID: 12396607
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Immunization with wild-type or CD4-binding-defective HIV-1 Env trimers reduces viremia equivalently following heterologous challenge with simian-human immunodeficiency virus.
    Sundling C; O'Dell S; Douagi I; Forsell MN; Mörner A; Loré K; Mascola JR; Wyatt RT; Karlsson Hedestam GB
    J Virol; 2010 Sep; 84(18):9086-95. PubMed ID: 20610729
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Cross-protection in NYVAC-HIV-1-immunized/HIV-2-challenged but not in NYVAC-HIV-2-immunized/SHIV-challenged rhesus macaques.
    Patterson LJ; Peng B; Abimiku AG; Aldrich K; Murty L; Markham PD; Kalyanaraman VS; Alvord WG; Tartaglia J; Franchini G; Robert-Guroff M
    AIDS; 2000 Nov; 14(16):2445-55. PubMed ID: 11101054
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Cellular immunity elicited by human immunodeficiency virus type 1/ simian immunodeficiency virus DNA vaccination does not augment the sterile protection afforded by passive infusion of neutralizing antibodies.
    Mascola JR; Lewis MG; VanCott TC; Stiegler G; Katinger H; Seaman M; Beaudry K; Barouch DH; Korioth-Schmitz B; Krivulka G; Sambor A; Welcher B; Douek DC; Montefiori DC; Shiver JW; Poignard P; Burton DR; Letvin NL
    J Virol; 2003 Oct; 77(19):10348-56. PubMed ID: 12970419
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Protective effects of nef-deleted SHIV or that having IFN-gamma against disease induced with a pathogenic virus early after vaccination.
    Enose Y; Kita M; Yamamoto T; Suzuki H; Miyake A; Horiuchi R; Ibuki K; Kaneyasu K; Kuwata T; Takahashi E; Sakai K; Shinohara K; Miura T; Hayami M
    Arch Virol; 2004 Sep; 149(9):1705-20. PubMed ID: 15593414
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Broad HIV-1 neutralizing antibody response induced by heterologous gp140/gp145 DNA prime-vaccinia boost immunization.
    Liu L; Hao Y; Luo Z; Huang Y; Hu X; Liu Y; Shao Y
    Vaccine; 2012 Jun; 30(28):4135-43. PubMed ID: 22561314
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Multiprotein HIV type 1 clade B DNA/MVA vaccine: construction, safety, and immunogenicity in Macaques.
    Smith JM; Amara RR; McClure HM; Patel M; Sharma S; Yi H; Chennareddi L; Herndon JG; Butera ST; Heneine W; Ellenberger DL; Parekh B; Earl PL; Wyatt LS; Moss B; Robinson HL
    AIDS Res Hum Retroviruses; 2004 Jun; 20(6):654-65. PubMed ID: 15242543
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Protection against chronic infection and AIDS by an HIV envelope peptide-cocktail vaccine in a pathogenic SHIV-rhesus model.
    Nehete PN; Chitta S; Hossain MM; Hill L; Bernacky BJ; Baze W; Arlinghaus RB; Sastry KJ
    Vaccine; 2001 Dec; 20(5-6):813-25. PubMed ID: 11738745
    [TBL] [Abstract][Full Text] [Related]  

  • 33. CD40L-adjuvanted DNA/modified vaccinia virus Ankara simian immunodeficiency virus SIV239 vaccine enhances SIV-specific humoral and cellular immunity and improves protection against a heterologous SIVE660 mucosal challenge.
    Kwa S; Lai L; Gangadhara S; Siddiqui M; Pillai VB; Labranche C; Yu T; Moss B; Montefiori DC; Robinson HL; Kozlowski PA; Amara RR
    J Virol; 2014 Sep; 88(17):9579-89. PubMed ID: 24920805
    [TBL] [Abstract][Full Text] [Related]  

  • 34. CD8 T Cells Show Protection against Highly Pathogenic Simian Immunodeficiency Virus (SIV) after Vaccination with SIV Gene-Expressing BCG Prime and Vaccinia Virus/Sendai Virus Vector Boosts.
    Kato S; Shida H; Okamura T; Zhang X; Miura T; Mukai T; Inoue M; Shu T; Naruse TK; Kimura A; Yasutomi Y; Matsuo K
    J Virol; 2021 Jan; 95(4):. PubMed ID: 33087465
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Intravenous inoculation of replication-deficient recombinant vaccinia virus DIs expressing simian immunodeficiency virus gag controls highly pathogenic simian-human immunodeficiency virus in monkeys.
    Izumi Y; Ami Y; Matsuo K; Someya K; Sata T; Yamamoto N; Honda M
    J Virol; 2003 Dec; 77(24):13248-56. PubMed ID: 14645581
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Replication-incompetent adenoviral vaccine vector elicits effective anti-immunodeficiency-virus immunity.
    Shiver JW; Fu TM; Chen L; Casimiro DR; Davies ME; Evans RK; Zhang ZQ; Simon AJ; Trigona WL; Dubey SA; Huang L; Harris VA; Long RS; Liang X; Handt L; Schleif WA; Zhu L; Freed DC; Persaud NV; Guan L; Punt KS; Tang A; Chen M; Wilson KA; Collins KB; Heidecker GJ; Fernandez VR; Perry HC; Joyce JG; Grimm KM; Cook JC; Keller PM; Kresock DS; Mach H; Troutman RD; Isopi LA; Williams DM; Xu Z; Bohannon KE; Volkin DB; Montefiori DC; Miura A; Krivulka GR; Lifton MA; Kuroda MJ; Schmitz JE; Letvin NL; Caulfield MJ; Bett AJ; Youil R; Kaslow DC; Emini EA
    Nature; 2002 Jan; 415(6869):331-5. PubMed ID: 11797011
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Characterization of simian and human immunodeficiency chimeric viruses re-isolated from vaccinated macaque monkeys after challenge infection.
    Kwofie TB; Miura T; Ibuki K; Enose Y; Suzuki H; Ui M; Kuwata T; Hayami M
    Arch Virol; 2002 Jun; 147(6):1091-104. PubMed ID: 12111421
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Highly effective control of an AIDS virus challenge in macaques by using vesicular stomatitis virus and modified vaccinia virus Ankara vaccine vectors in a single-boost protocol.
    Ramsburg E; Rose NF; Marx PA; Mefford M; Nixon DF; Moretto WJ; Montefiori D; Earl P; Moss B; Rose JK
    J Virol; 2004 Apr; 78(8):3930-40. PubMed ID: 15047809
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Different patterns of immune responses but similar control of a simian-human immunodeficiency virus 89.6P mucosal challenge by modified vaccinia virus Ankara (MVA) and DNA/MVA vaccines.
    Amara RR; Villinger F; Staprans SI; Altman JD; Montefiori DC; Kozyr NL; Xu Y; Wyatt LS; Earl PL; Herndon JG; McClure HM; Moss B; Robinson HL
    J Virol; 2002 Aug; 76(15):7625-31. PubMed ID: 12097576
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Immunization of rhesus macaques with a polyvalent DNA prime/protein boost human immunodeficiency virus type 1 vaccine elicits protective antibody response against simian human immunodeficiency virus of R5 phenotype.
    Pal R; Kalyanaraman VS; Nair BC; Whitney S; Keen T; Hocker L; Hudacik L; Rose N; Mboudjeka I; Shen S; Wu-Chou TH; Montefiori D; Mascola J; Markham P; Lu S
    Virology; 2006 May; 348(2):341-53. PubMed ID: 16460776
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 52.